@Septerna_Inc

A drug discovery company founded by Nobel Prize Laureate Dr. Bob Lefkowitz. Septerna has unlocked G-protein coupled receptors (GPCR) to the full suite of drug discovery tools with their native complex platform. GPCRs play an integral role in cellular signaling and are of high therapeutic interest. While there are FDA approved drugs that target this class, ~300 GPCRs of high therapeutic interest remain undrugged due to the inability to isolate GPCRs and feed them into modern drug development workflows. This lack of tools reduces the overall probability of success and, best case, produces drugs with adverse side effect profiles in the event discovery efforts are successful. Septerna has overcome these limitations with their native complex platform and is therefore uniquely positioned to develop first-in-class and best-in-class small molecule drugs against indications with high unmet need. With their competitive advantage in screening and pharmacology, Septerna is advancing five pre-clinical programs, each with blockbuster potential. Headquarters: San Francisco, CA Investment Date: September 2021 Catalio Investment: Preferred Stock Catalio LPs Co-Invest: No Catalio Deal Source: Dr. Bob Lefkowitz Key Executives: Jeff Finer (CEO) Technology Source: Duke University